中国临床药理学杂志Issue(2)：122-126,5.DOI:10.13699/j.cnki.1001-6821.2015.02.013
非布司他和别嘌醇治疗痛风有效性和安全性的Meta分析
Efficacy and safety of febuxostat versus allopurinol in the treatment of gout by Meta analysis
杨婷 1路敏 1周颖 1崔一民1
作者信息
- 1. 北京大学第一医院药剂科，北京 100034
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of febuxostat compared to allopurinol for the treatment of gout.Methods Randomized controlled trials ( RCTs ) of febuxostat were retrieved from PubMed , EmBase , the Cochrane Library , CNKI and CBM databases.Two revie-wers independently selected studies , assessed study quality , and extrac-ted data.According to the principles and methods of Cochrane systematic reviews , the included RCTs were analyzed by the software RevMan 5.2.7 provided by the Cochrane collaboration .Results Five studies were ulti-mately included in the analysis.Patients receiving febuxostat were more likely to achieve a serum uric acid ( sUA) of 6 mg· dL-1 than allopurinol recipients .The decline from baseline in sUA levels was more obvious in febuxostat group than allopurinol (P<0.05).However, febuxostat did not reduce the risk of gout flares compared with allopurinol .Overall , the risk of adverse drugs reaction was lower in febuxostat recipients than allopuri -nol.Conclusions Although febuxostat demonstrated a higher likelihood of achieving a target sUA level of <6 mg· dL-1 , however , there was no evidence that febuxostat is better than allopurinol for preventing gout flare .Taken its higher cost into consideration , febuxostat should not be the rou-tine option for chronic gout , except for those patients with renal dysfunction.关键词
非布司他/别嘌醇/有效性/安全性/痛风/Meta分析Key words
febuxostat/allopurinol/efficacy/safety/gout/Meta analysis分类
医药卫生引用本文复制引用
杨婷,路敏,周颖,崔一民..非布司他和别嘌醇治疗痛风有效性和安全性的Meta分析[J].中国临床药理学杂志,2015,(2):122-126,5.
